Do not mix w/ NaHCO3 or any alkaline solution. Diluted Solutions must be used within 24 hours.
During the administration of Dobutamine hydrochloride injection, as with any adrenergic agent, ECG and blood pressure should be continuously monitored. In addition, pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid in the safe and effective infusion of Dobutamine solution.
Hypovolemia should be corrected with suitable volume expanders before treatment with Dobutamine hydrochloride injection is instituted.
Animal studies indicate that dobutamine may be ineffective if the patient has recently received a β-blocking drug. In such a case, the peripheral vascular resistance may increase.
No improvement may be observed in the presence of marked mechanical obstruction, such as severe valvular aortic stenosis.
Usage Following Acute Myocardial Infarction: Clinical experience with Dobutamine hydrochloride injection following myocardial infarction has been insufficient to establish the safety of the drug for this use. There is concern that any agent that increases contractile force and heart rate may increase the size of an infarction by intensifying ischemia, but it is not known whether dobutamine does so.
It should be used w/ caution in patients with cardiogenic shock complicated by severe hypotension. Hypovolaemia should be corrected before treatment.
Pediatric Use: The safety and effectiveness of Dobutamine hydrochloride injection for use in children have not been studied.